Literature DB >> 18637993

Sacral neuromodulation for lower urinary tract dysfunction and impact on erectile function.

Giuseppe Lombardi1, Nicola Mondaini, Gianluca Giubilei, Angelo Macchiarella, Filippo Lecconi, Giulio Del Popolo.   

Abstract

INTRODUCTION: The first sacral nerve stimulators were for urinary urgency incontinence, urgency-frequency, and nonobstructive urinary retention. Since then, observations have been made for benefits beyond voiding disorders. AIM: To evaluate if sacral neuromodulation (SNM) using the InterStim system (Medtronic Inc., Minneapolis, MN, USA) improves erectile function.
METHODS: From January 1999 to January 2007, 54 males, mean age 42.8, underwent a permanent SNM for lower urinary tract symptoms (LUTS). Pre-SNM only subjects with concomitant erectile impairment according to the five-item version of the International Index of Erectile Function (IIEF-5), with normal blood sexual hormonal status, and responding to an intracavernous injection test 10 microg were enrolled in our study. Three months after permanent implantation, the IIEF-5 was completed again. Those who benefited significantly in erectile function completed the IIEF-5 semiannually. A final checkup was performed in July 2007. MAIN OUTCOME MEASURES: A score of IIEF-5 equal to or higher than 25% compared to baseline indicated remarkable clinical enhancement.
RESULTS: Presurgery, two patients were excluded. Overall, 22 subjects (42.3%) showed erectile impairment (14 were neurogenic). In the first visit post-SNM, five retentionists of neurogenic origin and two with overactive bladder syndrome of idiopathic origin achieved noticeable erectile improvement. Their median IIEF-5 score shifted from 14.6 to 22.2, and 15.5 to 22.5, respectively. During follow-up, two neurogenics lost the benefits concerning voiding and erection and recovered them after a new implant in the contralateral sacral S3 root. In the final visit, the seven responders reached an IIEF-5 score of at least 22.
CONCLUSIONS: Our study showed a clinically important benefit of sexual function mainly for neurogenic retentionists. Future research should test SNM in a larger sample of subjects, exclusively with sexual dysfunctions, in order to better understand the mechanism of action of SNM on erectile function.

Entities:  

Mesh:

Year:  2008        PMID: 18637993     DOI: 10.1111/j.1743-6109.2008.00948.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  6 in total

Review 1.  Sacral nerve modulation in overactive bladder.

Authors:  John A Occhino; Steven W Siegel
Journal:  Curr Urol Rep       Date:  2010-09       Impact factor: 3.092

Review 2.  Sacral neuromodulation stimulation for IC/PBS, chronic pelvic pain, and sexual dysfunction.

Authors:  Jennifer Yonaitis Fariello; K Whitmore
Journal:  Int Urogynecol J       Date:  2010-12       Impact factor: 2.894

3.  Pathogenic mechanisms linking benign prostatic hyperplasia, lower urinary tract symptoms and erectile dysfunction.

Authors:  Sidney Glina; Felipe Placco Araujo Glina
Journal:  Ther Adv Urol       Date:  2013-08

4.  Autonomic-somatic communications in the human pelvis: computer-assisted anatomic dissection in male and female fetuses.

Authors:  Bayan Alsaid; David Moszkowicz; Frédérique Peschaud; Thomas Bessede; Mazen Zaitouna; Ibrahim Karam; Stéphane Droupy; Gérard Benoit
Journal:  J Anat       Date:  2011-07-22       Impact factor: 2.610

Review 5.  Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study.

Authors:  G Lombardi; S Musco; J J Wyndaele; G Del Popolo
Journal:  Spinal Cord       Date:  2015-07-21       Impact factor: 2.772

Review 6.  [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].

Authors:  F Girtner; M Burger; R Mayr
Journal:  Urologe A       Date:  2019-06       Impact factor: 0.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.